Corbus Pharmaceuticals Holdings, Inc. (0SZI.L)
USD 7.95
(7.43%)
USD 7.95
(7.43%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 | -31.16 Million USD | -1994.81% |
| 2022 | -1.48 Million USD | -96.41% |
| 2021 | -757.52 Thousand USD | -119.73% |
| 2020 | 3.83 Million USD | -89.35% |
| 2019 | 36.05 Million USD | 182.33% |
| 2018 | -43.79 Million USD | -85.57% |
| 2017 | -23.59 Million USD | -74.48% |
| 2016 | -13.52 Million USD | -158.1% |
| 2015 | -5.24 Million USD | -317.37% |
| 2014 | -1.25 Million USD | 0.0% |
| 2013 | - USD | 0.0% |
| 2012 | - USD | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q1 | -151.68 Thousand USD | -112.62% |
| 2024 Q2 | -200 Thousand USD | -31.85% |
| 2023 Q1 | -363.74 Thousand USD | 2.8% |
| 2023 FY | -641 Thousand USD | 56.92% |
| 2023 Q4 | 1.2 Million USD | 886.48% |
| 2023 Q3 | -152.8 Thousand USD | 3.49% |
| 2023 Q2 | -158.34 Thousand USD | 56.47% |
| 2022 Q4 | -374.21 Thousand USD | 0.16% |
| 2022 Q3 | -374.79 Thousand USD | -1.19% |
| 2022 Q2 | -370.38 Thousand USD | -0.52% |
| 2022 Q1 | -368.45 Thousand USD | 66.97% |
| 2022 FY | -1.48 Million USD | -96.41% |
| 2021 Q1 | -10.07 Million USD | 34.81% |
| 2021 Q2 | -11.12 Million USD | -10.48% |
| 2021 Q3 | -8.21 Million USD | 26.15% |
| 2021 FY | -757.52 Thousand USD | -119.73% |
| 2021 Q4 | -1.11 Million USD | 86.43% |
| 2020 Q3 | -26.29 Million USD | 13.51% |
| 2020 Q2 | -30.39 Million USD | -37.02% |
| 2020 Q1 | -22.18 Million USD | -6.08% |
| 2020 FY | 3.83 Million USD | -89.35% |
| 2020 Q4 | -15.45 Million USD | 41.23% |
| 2019 Q3 | -19.56 Million USD | -382.97% |
| 2019 FY | 36.05 Million USD | 182.33% |
| 2019 Q1 | -19.89 Million USD | -43.63% |
| 2019 Q4 | -20.91 Million USD | -6.91% |
| 2019 Q2 | 6.91 Million USD | 134.74% |
| 2018 Q2 | -9.4 Million USD | -6.71% |
| 2018 Q1 | -8.81 Million USD | -80.62% |
| 2018 FY | -43.79 Million USD | -85.57% |
| 2018 Q4 | -13.85 Million USD | -18.24% |
| 2018 Q3 | -11.71 Million USD | -24.57% |
| 2017 Q3 | -4.82 Million USD | 10.85% |
| 2017 FY | -23.59 Million USD | -74.48% |
| 2017 Q2 | -5.41 Million USD | -6.72% |
| 2017 Q4 | -4.88 Million USD | -1.12% |
| 2017 Q1 | -5.07 Million USD | -1.36% |
| 2016 Q3 | -3.57 Million USD | -12.7% |
| 2016 FY | -13.52 Million USD | -158.1% |
| 2016 Q4 | -5 Million USD | -40.06% |
| 2016 Q2 | -3.17 Million USD | -78.38% |
| 2016 Q1 | -1.77 Million USD | -21.83% |
| 2015 Q4 | -1.45 Million USD | 0.37% |
| 2015 Q2 | -1.59 Million USD | -120.29% |
| 2015 Q1 | -723.43 Thousand USD | -26.57% |
| 2015 FY | -5.24 Million USD | -317.37% |
| 2015 Q3 | -1.46 Million USD | 8.11% |
| 2014 Q4 | -571.57 Thousand USD | -26.29% |
| 2014 FY | -1.25 Million USD | 0.0% |
| 2014 Q3 | -452.6 Thousand USD | -167.11% |
| 2014 Q2 | -169.44 Thousand USD | -173.66% |
| 2014 Q1 | -61.91 Thousand USD | 0.0% |
| 2013 Q3 | - USD | 0.0% |
| 2013 Q1 | - USD | 0.0% |
| 2013 Q2 | - USD | 0.0% |
| 2013 Q4 | - USD | 0.0% |
| 2013 FY | - USD | 0.0% |
| 2012 FY | - USD | 0.0% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| Editas Medicine, Inc. | -99.52 Million USD | 68.685% |
| Dynavax Technologies Corporation | 182.11 Million USD | 117.114% |
| Cara Therapeutics, Inc. | 14.79 Million USD | 310.678% |
| Walgreens Boots Alliance, Inc. | 26.52 Billion USD | 100.118% |
| Supernus Pharmaceuticals, Inc. | 523.74 Million USD | 105.951% |
| Perrigo Company plc | 1.68 Billion USD | 101.855% |
| Atara Biotherapeutics, Inc. | -313 Thousand USD | -9857.719% |
| Illumina, Inc. | 2.74 Billion USD | 101.136% |
| Thermo Fisher Scientific Inc. | 15.22 Billion USD | 100.205% |
| Nektar Therapeutics | 53.47 Million USD | 158.281% |
| Iovance Biotherapeutics, Inc. | -9.56 Million USD | -225.817% |
| IQVIA Holdings Inc. | 5.23 Billion USD | 100.595% |
| Heron Therapeutics, Inc. | 10.04 Million USD | 410.373% |
| Unity Biotechnology, Inc. | -19.69 Million USD | -58.22% |
| BioMarin Pharmaceutical Inc. | 1.9 Billion USD | 101.637% |
| Waters Corporation | 1.76 Billion USD | 101.77% |
| Biogen Inc. | 7.3 Billion USD | 100.427% |
| Sangamo Therapeutics, Inc. | -45.32 Million USD | 31.235% |
| Adicet Bio, Inc. | -6.09 Million USD | -411.113% |
| Evolus, Inc. | 140.52 Million USD | 122.179% |
| bluebird bio, Inc. | -4.03 Million USD | -673.391% |
| Aclaris Therapeutics, Inc. | -85.21 Million USD | 63.425% |
| Esperion Therapeutics, Inc. | 73.06 Million USD | 142.656% |
| FibroGen, Inc. | 128.9 Million USD | 124.179% |
| Agilent Technologies, Inc. | 3.46 Billion USD | 100.899% |
| Homology Medicines, Inc. | -7.22 Million USD | -331.148% |
| Geron Corporation | -123.5 Million USD | 74.764% |
| Alnylam Pharmaceuticals, Inc. | 1.51 Billion USD | 102.053% |
| Amicus Therapeutics, Inc. | 362.03 Million USD | 108.609% |
| Myriad Genetics, Inc. | 476.4 Million USD | 106.542% |
| Regeneron Pharmaceuticals, Inc. | 11.3 Billion USD | 100.276% |
| OPKO Health, Inc. | 318.12 Million USD | 109.797% |
| Viking Therapeutics, Inc. | -292 Thousand USD | -10573.856% |
| Intellia Therapeutics, Inc. | -398.79 Million USD | 92.185% |
| Zoetis Inc. | 5.83 Billion USD | 100.534% |
| Abeona Therapeutics Inc. | 302 Thousand USD | 10420.417% |
| Mettler-Toledo International Inc. | 2.16 Billion USD | 101.437% |
| Exelixis, Inc. | 1.75 Billion USD | 101.773% |
| Vertex Pharmaceuticals Incorporated | 8.6 Billion USD | 100.362% |
| uniQure N.V. | 2.21 Million USD | 1507.118% |
| Kala Pharmaceuticals, Inc. | -303 Thousand USD | -10186.356% |
| Anavex Life Sciences Corp. | - USD | Infinity% |
| Axsome Therapeutics, Inc. | 244.53 Million USD | 112.746% |
| Verastem, Inc. | -62 Thousand USD | -50170.419% |
| Imunon, Inc. | -720 Thousand USD | -4228.812% |
| Ionis Pharmaceuticals, Inc. | 778.51 Million USD | 104.003% |
| Sarepta Therapeutics, Inc. | 1.09 Billion USD | 102.852% |
| Neurocrine Biosciences, Inc. | 1.84 Billion USD | 101.687% |
| Corcept Therapeutics Incorporated | 475.89 Million USD | 106.549% |
| Halozyme Therapeutics, Inc. | 636.89 Million USD | 104.894% |
| TG Therapeutics, Inc. | 219.1 Million USD | 114.225% |
| Blueprint Medicines Corporation | 236.58 Million USD | 113.174% |
| Insmed Incorporated | 239.63 Million USD | 113.006% |
| Agios Pharmaceuticals, Inc. | 17.31 Million USD | 279.962% |
| Incyte Corporation | 3.44 Billion USD | 100.906% |
| Emergent BioSolutions Inc. | 343.9 Million USD | 109.063% |